Bandwidth, uniQure, and Stanley Black & Decker All Miss Q2 Estimates in Diverse Sector Sweep

The Quick Take

• Bandwidth Inc (BAND) Q2 revenue beat but EPS missed; EBITDA growth signals improving profitability trend
• uniQure NV (QURE) Q2 EPS and revenue missed consensus but highlighted regulatory pipeline progress
• Stanley Black & Decker (SWK) Q2 missed while maintaining full-year financial guidance
• The three misses span communications software, gene therapy biotech, and industrial tools — showing broad cost pressure

A diverse set of Q2 2026 earnings reports from Bandwidth Inc, uniQure NV, and Stanley Black & Decker reveals cost pressure and execution challenges across communications software, gene therapy biotechnology, and industrial tools. GuruFocus analysis shows each company has a distinct story: Bandwidth's cloud communications platform shows revenue growth and improving EBITDA, positioning it for eventual profitability despite near-term EPS misses; uniQure's gene therapy pipeline progress offers long-term promise while current commercialisation revenues remain limited; and Stanley Black & Decker's industrial and consumer tools business faces input cost and housing market headwinds.

The Stanley Black & Decker miss is perhaps the most economically significant of the three, given SWK's size and exposure to global consumer and industrial demand. SWK's tools business tracks housing activity, construction, and manufacturing sentiment. Its ability to maintain full-year guidance despite a Q2 miss suggests management expects H2 acceleration — likely tied to housing market recovery if the Fed eases rates. Bandwidth's improving EBITDA trajectory is a more optimistic signal for cloud communications infrastructure, where consolidation and pricing discipline are improving sector economics after the 2022-2023 froth unwinding.

Forward signals: for SWK, watch housing starts data and any indication of consumer tooling demand recovering in Q3; for BAND, watch net revenue retention and enterprise customer expansion metrics; for QURE, watch FDA and EMA interaction timelines for its hemophilia gene therapy candidate. The macro variable across all three is the interest rate environment — lower rates support housing (SWK), reduce cost of capital for biotech (QURE), and ease enterprise software budget pressures (BAND). A dovish Fed today would be broadly constructive for all three names into H2 2026.

Synthesized from 3 sources.